

The US Deprescribing Research Network

Pilot and Grant Planning Awards Information for Potential Applicants

AMANDA MIXON, MD

SANDRA SIMMONS, PHD


JOANNA GUPTA, MED

Disclosures

- No relevant disclosures
- Thank you!
 - NIA R24 AG064025-1
 - Scientific Advisory Board
 - Joanna Gupta, Malena Spar, Jonathan Norton, Anael Rizzo



What is the network?



Five pillars

- Investigator development
- Stakeholder engagement
- Data and resources
- Working Groups
- Funding for pilot studies and grant-planning activities

Pilot Awards: Purpose

- Support early-stage research in deprescribing that has high potential to develop into future larger projects
- Funding will be provided primarily, but not exclusively, to junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.



US Deprescribing Research Network

Advancing Research to Optimize Medication Use Among Older Adults

Investigator Initiated Proposal Guidelines (USDeN IIP 2020)

The U.S. Deprescribing Research Network is a collaborative research network with the overall goal to support development of investigators studying deprescribing for older adults and to catalyze a range of high-quality, clinically impactful research in this area. The challenges of excessive medication use, medication-related harms, and values-driven decision-making are especially pressing for older adults, particularly those with multiple chronic conditions. Solutions to these challenges require attention to geriatric principles, including (but not limited to) clinical complexity and multimorbidity, transitions across multiple providers and sites of care, older adults' values and priorities, and the shifting balance of medication benefits and harms in late life. Our overarching aim is to expand the quality, quantity, and translational impact of deprescribing research. Pilot grants up to \$60,000 in total costs (direct plus indirect funds) for a one-year period will be awarded to applicants seeking to further research efforts in this field as detailed in the following sections.

- 1) **Background:** Deprescribing is an essential component of safe and effective health care for older adults. Even with the most intensive efforts, it is difficult to prevent older adults from being started on medications that may cause more harm than benefit. In addition, medications that were once helpful for older adults may no longer be advisable to continue, either because the person has developed adverse effects, or because their clinical conditions, overall health, and/or goals of care may have changed since the medication was first prescribed.
- 2) **Research Objectives:** This funding opportunity is for studies designed to expand the quality, quantity, and translational impact of deprescribing research targeting older adults. Funding will be provided primarily, but not exclusively, to junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.
- 3) **Population of Interest:** The study must focus on deprescribing efforts impacting older adults and may include an emphasis on patients with multiple chronic conditions, including those with special vulnerabilities, such as dementia.
- 4) **Research Methodology:** Research is needed in a broad range of areas which include, but are not limited to, delineating the clinical outcomes of deprescribing, identifying behavioral and communication techniques that can constructively engage patients on this topic, determining the effectiveness of deprescribing interventions, and addressing the needs of underserved groups. Different study designs are needed to answer these questions – from pilot research that may lead to future clinical trials, to observational studies, to in-depth qualitative evaluation.
- 5) **Funds available:** Maximum period of performance is one year. The anticipated total award (directs + indirects) for this grant opportunity is a maximum of \$60,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. The combined budgeted total costs will not exceed \$60,000 or use an indirect cost rate exceeding each organization's negotiated rate. The possibility of funding exceeding \$60,000 or a period greater than one year may be considered with special permission; initiate such a request as early as possible through an email to admin@deprescribingresearch.org

RFA Investigator Initiated Proposal – November 2019

Pilot and Grant Planning Awards: Types



- Pilot Award
- Grant Planning Award

For full descriptions, refer to:

<https://deprescribingresearch.org/network-activities/grant-opportunities/>



US Deprescribing Research Network

Advancing Research to Optimize Medication Use Among Older Adults

Investigator Initiated Proposal Guidelines (USDeN IIP 2020)

The U.S. Deprescribing Research Network is a collaborative research network with the overall goal to support development of investigators studying deprescribing for older adults and to catalyze a range of high-quality, clinically impactful research in this area. The challenges of excessive medication use, medication-related harms, and values-driven decision-making are especially pressing for older adults, particularly those with multiple chronic conditions. Solutions to these challenges require attention to geriatric principles, including (but not limited to) clinical complexity and multimorbidity, transitions across multiple providers and sites of care, older adults' values and priorities, and the shifting balance of medication benefits and harms in late life. Our overarching aim is to expand the quality, quantity, and translational impact of deprescribing research. Pilot grants up to \$60,000 in total costs (direct plus indirect funds) for a one-year period will be awarded to applicants seeking to further research efforts in this field as detailed in the following sections.

- 1) **Background:** Deprescribing is an essential component of safe and effective health care for older adults. Even with the most intensive efforts, it is difficult to prevent older adults from being started on medications that may cause more harm than benefit. In addition, medications that were once helpful for older adults may no longer be advisable to continue, either because the person has developed adverse effects, or because their clinical conditions, overall health, and/or goals of care may have changed since the medication was first prescribed.
- 2) **Research Objectives:** This funding opportunity is for studies designed to expand the quality, quantity, and translational impact of deprescribing research targeting older adults. Funding will be provided primarily, but not exclusively, to junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.
- 3) **Population of Interest:** The study must focus on deprescribing efforts impacting older adults and may include an emphasis on patients with multiple chronic conditions, including those with special vulnerabilities, such as dementia.
- 4) **Research Methodology:** Research is needed in a broad range of areas which include, but are not limited to, delineating the clinical outcomes of deprescribing, identifying behavioral and communication techniques that can constructively engage patients on this topic, determining the effectiveness of deprescribing interventions, and addressing the needs of underserved groups. Different study designs are needed to answer these questions – from pilot research that may lead to future clinical trials, to observational studies, to in-depth qualitative evaluation.
- 5) **Funds available:** Maximum period of performance is one year. The anticipated total award (directs + indirects) for this grant opportunity is a maximum of \$60,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. The combined budgeted total costs will not exceed \$60,000 or use an indirect cost rate exceeding each organization's negotiated rate. The possibility of funding exceeding \$60,000 or a period greater than one year may be considered with special permission; initiate such a request as early as possible through an email to admin@deprescribingresearch.org

RFA Investigator Initiated Proposal – November 2019

Scope of Pilot Grants

Scope of Pilot Projects

Projects should:

- Have a direct and clear relationship to deprescribing
- Be relevant to the care of older adults
- Demonstrate a clear pathway to future grants, research opportunities, and/or career development focused on deprescribing

Scope: Definition of Deprescribing

‘Deprescribing is the process of withdrawal, dose reduction or substitution of an inappropriate (high risk, unnecessary, low benefit) medication, supervised by a health care professional with the goal of managing polypharmacy (also relevant for those without ‘polypharmacy’) and improving outcomes.’

-University of South Australia

See also: <https://deprescribingresearch.org/about-us/what-is-deprescribing/>

Pilot and Grant Planning Awards--Year 1

- Decisions about anticoagulation in patients with atrial fibrillation and dementia (Greg Ouellet, MD, MHS, Yale)
- Older adults' attitudes and preferences about how deprescribing recommendations are discussed (Ariel Green, MD, MPH, PhD and Nancy Schoenborn, MD, Johns Hopkins)
- Intensification and deintensification of glucose-lowering therapies among older adults with diabetes mellitus and multiple chronic conditions (Jen Kuntz, PhD, Kaiser Permanente Northwest)



Eligibility Criteria

Applicant Eligibility

- Hold a Doctoral degree (MD, PhD or equivalent)
- Employed as faculty, research scientist or equivalent position by start date of award
- Work in a college, university, medical or nursing school, or other fiscally responsible institution registered with System Award Management (SAM)
- Only one application per individual but two or more are allowed from the same institution



Applicant Eligibility Continued

- Eligible researchers at non-US institutions will be considered, but articulate how the proposed research will apply outside the home country, including the U.S.
- Applicants from under-represented racial and ethnic groups, socioeconomically-disadvantaged backgrounds, as well as individuals with disabilities encouraged to apply



Available Funds

Available Funds

- Up to \$60,000 in total costs (direct + indirect)
 - Indirect costs charged by recipient institution's federally negotiated rate
 - Foreign organizations may charge no more than 8% of modified total direct costs
- Distributed in August or September 2020 for use over a one-year period
- Three to five pilot awards per year



First Funding Mechanism: Pilot Award

Funding will be provided primarily but not exclusively to junior investigators

Proposed study provides preliminary data, proof of concept, or developmental work that provides a clear pathway to future larger-scale studies

Different study designs are encouraged, including pilot research that may lead to future clinical trials, observational studies, and/or in-depth qualitative evaluation.



Second Funding Mechanism: Grant Planning Award

Funding will be provided primarily but not exclusively to more established investigators

Researcher must be focused on grant planning activities that will lead to a larger research proposal



Submission Materials

Letters of Intent

Optional but encouraged, especially when:

- Requesting more than the budget cap or >1 year of funding (in special circumstances); feedback sought
- Details to include:
 - Research team
 - Stakeholder engagement
 - Aims, approach, and/or grant-planning activities
- Guidelines: <https://deprescribingresearch.org/network-activities/grant-opportunities/>
- Submit to: admin@deprescribingresearch.org

Formatting: 1 page, ½" margins, 11-point Arial font

Due Monday, February 10, 2020, 11:59 PM (PST)



Pilot and Grant Planning Awards: Requirements

Sections	Pilot	Grant Planning
Study Aims	✓	✓
Significance	✓	✓
Innovation	✓	✓
Approach	✓	✓
Future Directions	✓	✓
Stakeholder Engagement	✓	✓

Maximum of 5 pages (including cover), ½" margins, 11-point Arial font
Due Monday, March 9, 2020, 11:59 (PST)

Grant Planning Award

Additional Required Sections:

- Grant Planning Activities—aims and approaches for larger-scale study
- Funding Mechanisms—how work will lead to grants, publications, etc.



Both RFA's

Stakeholder Engagement:

- | |
|--|
| • Description of stakeholders |
| • Details on their engagement |
| • Information on how they will inform work |
| • Timeline of their study-related activities |
| • Settings and methods of engagement |



Required Supplemental Materials

- Half-page project description in lay terminology for stakeholders
- NIH-style biosketch
- Junior investigators:
 - One-page mentoring plan
 - Mentor's letter of support
- Budget forms



Required Supplemental Materials Continued


Budget Forms:

Budget summary
Budget justification
Scope of work
F&A rate agreement




Does not count toward 5 page limit
Due Monday, March 9, 2020, 11:59 (PST)

Submit Online



The screenshot shows the website for the US Deprescribing Research Network. The URL <https://deprescribingresearch.org/network-activities/grant-opportunities/> is highlighted in the browser's address bar. The website features a blue navigation bar with links to ABOUT US, NETWORK ACTIVITIES, NEWS, RESOURCES, MEMBERSHIP, and FOR PATIENTS. The main content area is titled "Grant Opportunities" and includes a paragraph about the network's funding goals and a list of links to learn more about various grant programs. A sidebar on the right lists additional resources like Investigator Development, Grant Opportunities, Engaging Stakeholders, Data and Resources, Working Groups, and Webinars.

<https://deprescribingresearch.org/network-activities/grant-opportunities/>

 US Deprescribing Research Network [Join the Network](#) [Twitter](#) [Search](#)

[ABOUT US](#) [NETWORK ACTIVITIES](#) [NEWS](#) [RESOURCES](#) [MEMBERSHIP](#) [FOR PATIENTS](#)

Grant Opportunities

The network funds pilot and exploratory studies, grant planning activities, and small collaboration grants. The goals of these grant programs are to support early-stage research in deprescribing that has high potential to develop into future large projects, to catalyze research in areas that are of particular importance to the field, to support junior investigator development, and to promote collaborations that will lead to future research projects.

- [Learn about and apply for a pilot or exploratory studies award](#)
- [Learn about and apply for a grant planning award](#)
- [Learn about and apply for a collaboration award](#)
- [Learn about network grantees and their projects](#)

[Investigator Development](#)

[Grant Opportunities](#)

[Engaging Stakeholders](#)




[Data and Resources](#)

[Working Groups](#)


[Webinars](#)

Submit Online

https://deprescribingresearch.org/elementor-413/

 US Deprescribing Research Network [Join the Network](#)  

[ABOUT US](#) [NETWORK ACTIVITIES](#) [NEWS](#) [RESOURCES](#) [MEMBERSHIP](#) [FOR PATIENTS](#)



USDeN RFA Grant Opportunity Submission

Please complete all fields and refer back to the application instructions for guidance. If you encounter any problems with your submission, please email admin@deprescribingresearch.org

First name *

Last name *

Email *
example@example.com

Institution *

Type of award ☐ Pilot or exploratory study
☐ Grant planning award

Application Upload *
Only .pdf, .doc, and .docx are accepted

Key Dates

Letters of Intent (optional)	Monday, February 10, 2020, 11:59 PM (PST)
Full application	Monday, March 9, 2020, 11:59 (PST)
Awards announced	June 1, 2020
Beginning of funding for selected awards	August or September 2020

Expectations and Resources for Awardees

Expectations and Resources

Year End Progress Report

Present Work at the
Annual Meeting

Yearly Online Surveys After
Award Period

Additional Expectations and Resources for Junior Investigators

Quarterly Calls with Pilot
Core

Quarterly Calls with
Stakeholder Engagement
Core

Optional USDeN Webinars
and Work-in Progress
Seminars

First Annual USDeN Meeting

May 6th, 2020, Long Beach, CA

KEYNOTE: CARA TANNENBAUM, MD, MSC

CO-FOUNDER AND CO-DIRECTOR OF THE
CANADIAN DEPRESCRIBING NETWORK



- Share research
- Access resources of USDeN
- Stakeholder engagement
- Networking
- Junior Investigator Supports

AND MORE....!

JAMA | Original Investigation

**Effect of a Pharmacist-Led Educational Intervention
on Inappropriate Medication Prescriptions in Older Adults
The D-PRESCRIBE Randomized Clinical Trial**

Philippe Martin, PhD; Robyn Tamblyn, PhD; Andrea Benedetti, PhD; Sara Ahmed, PhD; Cara Tannenbaum, MD, MSc

Upcoming Webinar

- Tues, February 4, 2020 at 2pm Eastern
- Shed-MEDS – A Hospital-based Deprescribing Trial Among Older Patients Transferred to Post-Acute Care
- Sandra Simmons, PhD and Ed Vasilevskis, MD, MPH




Junior Investigator Intensive Program

- The US Deprescribing Research Network seeks applicants for its 2020-2021 Junior Investigator Intensive Program in deprescribing research
- Program components:
 - Special evening meeting following the Annual Meeting on May 6, 2020 in Long Beach, CA
 - Monthly web-based meetings
 - Access to USDeN resources
- Applications due: March 1, 2020
- Visit deprescribingresearch.org for more information



DeprescribingResearch.org



Questions or Comments